Highest uptake (whole organ) occurred in lungs (22% Dose; weight ∼1246 g), liver (23%; weight ∼1677 g) and intermediate in brain (10%; weight ∼1600 g).
Secondary outcome measures included changes in hypoglycaemic drugs (type and dose), weight, body mass index, waist circumference, blood pressure, fasting plasma glucose, and lipid profile.
When both agents are administered in submaximal doses, weight gain and fluid retention from the TZD are reduced, as are gastrointestinal side effects of metformin.
IBW is the recommended dosing weight in obese patients.
Pharmacodynamic endpoints have greater weight in dose and schedule decisions, and the expectation of objective responses in phase I trials are more prominent.
Radioimmunotherapy resulted in dose-dependent, transient weight loss and myelotoxicity.
The administration of 2.5 and 5 MBq 211At-BR96 resulted in dose-dependent relative weight losses of 3% (range 1% to 6% and 55% (range 4%to8%8%), respectively, the nadir being seen on the first recording after treatment (day 2 p.i).
They were administered antitubercular therapy (Rifampicin, INH, Ethambutol and Pyrazinamide) in doses appropriate for weight.
As demonstrated in Table 6, all test doses of the extract significantly reduced the intestinal weight ratio in dose dependent manner.
Mice treated with extracts of A. integrifolia, C. myricoides, M. azedarach and P. vogelii significantly prevented weight loss in dose dependant fashion.
